Gemphire's cholesterol drug shows promise in Phase 2

Gemcabene, in-licensed from Pfizer, showed strong efficacy and safety in a handful of patients with a rare genetic disorder. But questions remain about the drug's future.

By Jacob Bell • June 29, 2017

Teva partner flunks second program this year

Xenon reported its topical pain drug missed all its endpoints. The failure follows a misstep with its acne program in March.

By Lisa LaMotta • June 28, 2017

Explore the Trendline➔

Radiopharmaceuticals

A series of technological advances have led to an explosion of scientific progress — and dealmaking — involving medicines that can precisely deliver radioactive materials into tumors.   

By BioPharma Dive staff

Early results show promise for Ra's rare disease drug

The biotech is touting positive results from two PNH patients in its Phase 2 trial, indicating it will open enrollment for a switching phase of the study.   

By Jacob Bell • June 28, 2017

Innate becomes the latest loser in MS

The Australian biotech, which has several big-name investors, lost most of its value after reporting a mid-stage loss.

By Lisa LaMotta • June 27, 2017

Merck succeeds where others failed, but skepticism abounds

The big pharma reported positive data for its CETP inhibitor; a class plagued by a string of failures. Yet, prospects for the drug are still unclear.

By Lisa LaMotta • June 27, 2017

Alder scores CGRP win but investors not impressed

Shares in the Washington biotech fell by a fifth in early Tuesday trading despite positive results from a Phase 3 study testing the migraine drug eptinezumab. 

By Ned Pagliarulo • June 27, 2017

Alnylam lines up Phase 3 for another RNAi drug

Early results from givosiran in acute hepatic porphryia gives the biotech confidence it can launch a Phase 3 program by the end of this year. 

By Ned Pagliarulo • June 26, 2017

Neothetics reduced to nothing after failed double chin trial

The tiny biotech will need to evaluate options for the future now that its only drug has failed. 

By Lisa LaMotta • June 26, 2017

Seattle Genetics' Adcetris succeeds in study but shares slide

Positive results for Adcetris in a key Phase 3 study could help expand the label for the blood cancer drug, but markets didn't appear encouraged. 

By Ned Pagliarulo • June 26, 2017

OSE stock tumbles on trial pause

The investors are looking askance at OSE Immunotherapeutics as temporary halt on lung cancer study wallops the company's value.

By Suzanne Elvidge • June 26, 2017

Roche's could-be hemophilia blockbuster scores in clinic

Nearly 63% of patients taking emicizumab had no bleeds during the median observation time versus 5.6% in the active comparator arm.

By Jacob Bell • June 26, 2017

Prescribed Reading: What we know from BIO

A closer look at the trends everyone was talking about at BIO, FDA continues its approval spree and Novartis has heart. 

By Lisa LaMotta • June 23, 2017

End-to-end drug & diagnostic development support for a new immuno-oncology agent: A case study

Immuno-oncology drug development is inherently complex and requires special considerations across the entire spectrum.

June 22, 2017

Low on cash, ImmunoCellular halts study and looks for a lifeline

The microcap biotech is evaluating "strategic alternatives," including a potential merger, restructuring or sale.

By Suzanne Elvidge • June 22, 2017

#BIO2017 Day 3 roundup: Building value and what it costs

There was a lot going on Wednesday at the BIO International Convention, as well as in and around the San Diego area — a major biotech hub. 

By Lisa LaMotta • June 21, 2017

#BIO2017 Day 2 roundup: A dearth of deals and Hung on Alzheimer's

The BIO International Convention was in full swing on Tuesday with high-profile talks, company presentations and panels on the state of the industry.

By Lisa LaMotta • June 20, 2017

Novartis eyes Regeneron's blockbuster Eylea franchise

Brolucizumab, pegged for a blockbuster future by Novartis, matched up to Regeneron's eye drug across two Phase 3 studies. 

By Jacob Bell • June 20, 2017

Gene therapy: What you need to know

As several promising gene therapies near potential approval, BioPharma Dive explored the challenges and commercial hurdles the treatments could face. 

By Lisa LaMotta • June 19, 2017

Safety concerns sideline Seattle Genetics' cancer candidate

The West Coast drugmaker stopped vadastuximab talirine investigations after the treatment arm of a Phase 3 study showed a higher rate of death.

By Jacob Bell • June 19, 2017

Humira shows its staying power

Pfizer had hoped head-to-head data comparing its JAK inhibitor Xeljanz to Humira would help steal market share, but the newer drug showed mixed results. 

By Suzanne Elvidge • June 19, 2017

Clovis soars on strong results for PARP inhibitor

Results from the ARIEL-3 study could expand Rubraca's market opportunity and position the drug more competitively versus rivals.

By Ned Pagliarulo • June 19, 2017

Prescribed Reading: ADA, Mylan, and an executive order?

The SGLT-2 category heats up at ADA, Mylan faces pressure from all sides, and President Trump might put his stamp on drug pricing.

By Lisa LaMotta • June 16, 2017

DIA: Exploring the impact of data and informatics technologies throughout the clinical trial journey

Sponsors are turning to intelligent, informatics-based solutions to help ensure that clinical trials are proceeding in the most effective manner possible.   

June 15, 2017

Aldeyra eyes Phase 3 after flunking Phase 2b

The biotech is itching to get on with a late-stage study of its eye allergy drug, which missed the primary endpoint of an earlier investigation.

By Suzanne Elvidge • June 15, 2017

How Merck hopes to win in I/O combos: Q&A with Roy Baynes

Combinations are pegged as the next step forward in immuno-oncology. Speaking with BioPharma Dive at ASCO, Merck's Roy Baynes cautioned how little is known about the best pairing and explained why monotherapy remains relevant.

By Ned Pagliarulo • June 14, 2017